Ginsenoside Rg1 inhibits proliferation of vascular smooth muscle cells stimulated by tumor necrosis factor-α

Acta Pharmacologica Sinica

Volumn 27, Issue 8, 2006, Pages 1000-1006

  Ma, Zeng Chun ^a   Gao, Yue ^a   Wang, Yu Guang ^a   Tan, Hong Ling ^a   Xiao, Cheng Rong ^a   Wang, Sheng Qi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Cell cycle; Ginsenoside Rg1; Proteomics; Tumor necrosis factor ; Vascular smooth muscle cells

Indexed keywords

G PROTEIN COUPLED RECEPTOR KINASE; GINSENOSIDE RG 1; PROTEIN KINASE C ZETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; DOSE RESPONSE; FLOW CYTOMETRY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; G1 PHASE; GINSENOSIDES; MALE; MYOCYTES, SMOOTH MUSCLE; PANAX; PLANTS, MEDICINAL; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746421519     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00331.x     Document Type: Article

References (23)

1. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999; 58: 1685-93.
2. Chen X. Cardiovascular protection by ginsenosides and their nitric oxide releasing action. Clin Exp Pharmacol Physiol 1996; 23: 728-32.
3. Kang SY, Schini-Kerth VB, Kim ND. Ginsenosides of the protopanaxatriol group cause endothelium-dependent relaxation in the rat aorta. Life Sci 1995; 56: 1577-86.
4. Lv JP, Ma ZC, Yang J, Huang J, Wang SR, Wang SQ. Ginsenoside Rg1-induced alterations in gene expression in TNF-α stimulated endothelial cells. Chin Med J 2004; 117: 871-7.
5. Kaji T, Okabe M, Shimada S, Yamamoto C, Fujiwara Y, Lee JB, et al. Sodium spirulan as a potent inhibitor of arterial smooth muscle cell proliferation in vitro. Life Sci 2004; 74: 2431-9.
6. Faries PL, Rohan DI, Wyers MC, Marin ML, Hollier LH, Quist WC, et al. Vascular smooth muscle cells derived from atherosclerotic human arteries exhibit greater adhesion, migration and proliferation than venous cells. J Surg Res 2002; 104: 22-8.
7. Wilkins MR, Sanchez JC, Gooley AA, Appel RD. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 1996; 13: 19-50.
8. Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 1998; 19: 1853-61.
9. Yong ZH, Jie Y, Guang RZ, Ying JY. Ferulic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II. Eur J Pharmacol 2004; 499: 85-90.
10. Ying W, Zhang K, Qian X, Xie L, Wang J, Xiang X, et al. Proteome analysis on an early transformed human bronchial epithelial cell line, BEP2D, after alpha-particle irradiation. Proteomics 2003; 3: 64-72.
11. Steiner S, Gatlin CL, Lennon JJ, McGrath AM, Aponte AM, Makusky AJ, et al. Proteomics to display lovastatin-induced protein and pathway regulation in rat liver. Electrophoresis 2000; 21: 2129-37.
12. Lim H, Eng J, Yates JR, Tollaksen SL, Giometti CS, Holden JF, et al. Identification of 2D-gel proteins: a comparison of MALDI/ TOF peptide mass mapping to mLC-ESI tandem mass spectrometry. J Am Soc Mass Spectr 2003; 14: 957-70.
13. Rivard A, Andres V. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol Histopathol 2000; 15: 557-71.
14. Ferguson JE, Patterson C. Break the cycle: the role of cell-cycle modulation in the prevention of vasculoproliferative diseases. Cell Cycle 2003; 2: 211-9.
15. Boehm M, Nabel EG. The cell cycle and cardiovascular diseases. Prog Cell Cycle Res 2003; 5: 19-30.
16. Lee B, Moon SK. Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscle cells. J Nutr 2005; 135: 2767-73.
17. 1 p21-associated cell cycle arrest. Biochem Pharmacol 2004; 67: 1907-16.
18. Fukui R, Shibata N, Kohbayashi E, Amakawa M, Furutama D, Hoshiga M, et al. Inhibition of smooth muscle migration by the p21 cyclin-dependent kinase. Atherosclerosis 1997; 132: 53-9.
19. Ginnan R, Pfleiderer PJ, Pumiglia K, Singer HA. PKC-delta and CaMKII-delta mediate ATP-dependent activation of ERK1/2 in vascular smooth muscle. Am J Physiol Cell Physiol 2004; 286: C1281-9.
20. Scott MT, Ingram A, Ball KL. PDK1-dependent activation of atypical PKC leads to degradation of the p21 tumour modifier protein. EMBO J 2002; 21: 6771-80.
21. Park JW, Jang MA, Lee YH, Passaniti A, Kwon TK. p53-Independent elevation of p21 expression by PMA results from PKC-mediated mRNA stabilization. Biochem Biophys Res Commun 2001; 280: 244-8.
22. Yang CM, Chien CS, Hsiao LD. Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol 2001; 132: 1531-41.
23. Minamino T, Yoshida T, Tateno K, Miyauchi H, Zou Y, Toko H, et al. Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis. Circulation 2003; 108: 2264-9.